CLINICAL DOSSIER
Cerebral palsy
A group of permanent disorders of movement and posture caused by damage to the developing brain. Cell therapy targets neuroprotection, remyelination and reduction of chronic neuroinflammation.
Open the dossierTREATMENTS · ATLAS
BEFOREYOUTHEMAPOFCELLTHERAPY
8 directions · 40 indications · 10 clinical dossiers
ACT 01·Neurology
Neurology
Cerebral palsy, autism, stroke, Parkinson's, ALS, spinal cord injuries, Alzheimer's, TBI, epilepsy, MS, dementia — living-cell neuroregenerative therapy.
Indication 1 of 11
ACT 02·Autoimmune
Autoimmune
SLE, rheumatoid arthritis, psoriasis, scleroderma — immunomodulation with mesenchymal cells.
CLINICAL DOSSIER
Systemic lupus erythematosus (SLE)
A chronic systemic autoimmune disease with damage to the skin, joints, kidneys, lungs, and central nervous system. Cell therapy modulates the autoimmune response, reduces the need for steroids and cytostatics, and slows damage to target organs.
Open the dossierIndication 1 of 4
ACT 03·Cardiovascular
Cardiovascular
MI, heart failure, ischemic cardiomyopathy, dilated cardiomyopathy, atherosclerosis — myocardial regeneration.
CLINICAL DOSSIER
Myocardial infarction
Acute ischaemia and necrosis of a heart muscle area due to coronary artery occlusion. Cell therapy in the subacute and chronic periods targets myocardial regeneration, angiogenesis, and improvement of ejection fraction.
Open the dossierIndication 1 of 5
ACT 04·Endocrinology
Endocrinology
Type 1 and type 2 diabetes, diabetic complications, hormonal disorders.
CLINICAL DOSSIER
Type 2 diabetes mellitus
A chronic metabolic disease with insulin resistance and relative insulin deficiency. Cell therapy reduces systemic inflammation, improves tissue insulin sensitivity, and supports residual pancreatic β-cell function.
Open the dossierIndication 1 of 4
ACT 05·Gynecology
Gynecology
Premature ovarian failure, uterine adhesions, reproductive health.
CLINICAL DOSSIER
Premature ovarian failure (POF)
Decline or cessation of ovarian function in women under 40 with oestrogen deficiency and fertility impairment. Cell therapy targets ovarian tissue regeneration, restoration of the follicular pool, and normalisation of the hormonal profile.
Open the dossierIndication 1 of 3
ACT 06·Orthopedics
Orthopedics
Osteoarthritis, avascular necrosis, osteoporosis, delayed fracture healing, tendon and ligament injuries.
CLINICAL DOSSIER
Osteoarthritis
A chronic degenerative joint disease with cartilage destruction, subchondral bone remodelling, and osteophyte formation. Cell therapy targets cartilage regeneration, reduction of inflammation, and pain relief.
Open the dossierIndication 1 of 5
ACT 07·Gastroenterology
Gastroenterology
Liver fibrosis and cirrhosis, liver failure, Crohn's disease, ulcerative colitis.
CLINICAL DOSSIER
Liver cirrhosis
A chronic progressive liver disease with replacement of parenchyma by connective tissue and disruption of organ architecture. Cell therapy targets reduction of fibrogenesis, hepatocyte regeneration, and improvement of liver function parameters.
Open the dossierIndication 1 of 5
ACT 08·Hematology
Hematology
Hematopoietic recovery, prevention of graft-versus-host disease (GVHD).
CLINICAL DOSSIER
GVHD prevention (graft-versus-host disease)
Graft-versus-host disease — an immune complication after allogeneic bone marrow or haematopoietic stem cell transplantation. Mesenchymal cell therapy reduces the risk of acute and chronic GVHD through potent immunomodulation.
Open the dossierIndication 1 of 2
INTERMISSION · 09
Not sure which direction fits your case?
Describe your case — the academic board will review the history and recommend a protocol that may apply.
FINALE · ASSESSMENT
Describe your case — the academic board will reply
Fill in a short request or the detailed medical form. The academic board reviews each case individually and does not accept patients with active oncology, uncontrolled epilepsy, or current acute infections.
Medical questionnaire · 10–15 min
Speed up your consultation
If you are ready to share the medical history and documents in advance, please fill out the detailed questionnaire. This helps the academic board prepare a personal protocol before the first conversation.